image dons

I make a donation

ALBATROSS

National multicentric randomized trial comparing specific aldosterone blockade on top of the usual treatment versus only the usual treatment, started within the 72 first hours after an acute myocardial infarct

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

National multicentric randomized trial comparing specific aldosterone blockade on top of the usual treatment versus only the usual treatment, started within the 72 first hours after an acute myocardial infarct.

date de réalisation

2010

nombre de patients

1622

nombre de centres participants

28 french centers

type de financement

Public (APHP & ICAN)

Référence

NCT01059136

Aldosterone Blockade Early After Acute Myocardial Infarction (ALBATROSS)

Study Description

The blockade of the renin-angiotensin-aldosterone (RAA) pathway by angiotensin conversion enzyme inhibitors (ACEI) is one corner stone in the management of heart failure as well as the management of ischemic heart disease, especially after acute myocardial infarctionHigh plasma aldosterone levels have been associated with both direct and indirect toxic effects on myocardium. ACEIs are associated with partial and temporary reduction of plasma aldosterone levels. The RALES randomized controlled trial has shown a reduction of mortality associated with the use of the selective aldosterone receptor blocker spironolactone, on top of standard therapy including ACEIs in the setting of NYHA 3-4 chronic heart failure. The EPHESUS randomized controlled trial has shown a reduction of mortality associated with the use of another selective aldosterone receptor blocker Eplerenone, initiated 3 to 14 days after acute myocardial infarction complicated by clinical heart failure and left ventricular ejection fraction <40&. Both previous studies have also reported a rapid reduction of global and arrhythmia-related mortality, within 30 days after the initiation of the medication.Such benefit has been reported after delayed initiation of aldosterone blocked, while aldosterone is at its highest level at presentation after acute myocardial infarction, with a rapid decrease within days after admission. Furthermore high aldosterone levels on admission are associated with adverse outcome independent of heart failure.
The hypothesis of the ALBATROSS trial : an early blockade of aldosterone receptors initiated at the first medical contact after acute myocardial infarction may reduce major cardiovascular events within 6 months after the occurrence of the myocardial infarction.

source clinicaltrials.gov

Publications

  • Early Aldosterone Blockade in Acute Myocardial Infarction : The ALBATROSS Randomized Clinical Trial
    Farzin Beygui, Guillaume Cayla, Vincent Roule, François Roubille, Nicolas Delarche, Johanne Silvain, Eric Van Belle, Loic Belle, Michel Galinier, Pascal Motreff, Luc Cornillet, Jean-Philippe Collet, Alain Furber, Patrick Goldstein, Patrick Ecollan, Damien Legallois, Alain Lebon, Hélène Rousseau, Jacques Machecourt, Faiez Zannad, Eric Vicaut, Gilles Montalescot, ALBATROSS Investigators
    Publicated in Journal of the American College of Cardiology
  • Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial
    Farzin Beygui, Eric Vicaut, Patrick Ecollan, Jacques Machecourt, Eric Van Belle, Faiez Zannad, Gilles Montalescot
    Publicated in American Heart Journal

Presentation

Autres études

+

ABYSS

En cours


Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.
+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients